A Phase 1/2, Randomized, Dose-finding/Dose-confirmation Study to Evaluate the Reactogenicity, Safety and Immunogenicity of mRNA-based Multivalent Seasonal Influenza Vaccine Candidates Administered in Healthy Younger and Older Adults
Latest Information Update: 09 May 2025
At a glance
- Drugs GSK 4382276 A (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
Most Recent Events
- 11 Mar 2025 Status changed from active, no longer recruiting to completed.
- 24 Jan 2024 Phase of this trial has been amended from Phase 1/2 to Phase 1.
- 24 Jan 2024 Status changed from recruiting to active, no longer recruiting.